An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies targeting cancer and autoimmune and inflammatory diseases.

Orange Grove Bio LLC of Cincinnati will provide investment and commercialization expertise to translate Pitt’s lab research into medicines and startup biotech companies, part of the university’s continuing pivot toward generating revenue from basic research that began under Chancellor Patrick Gallagher. The Orange Grove partnership, which will include internships for Pitt’s doctoral students, reflects a shift in how drugs are developed, according to Joe Havrilla, associate vice chancellor of innovation and entrepreneurship, a newly created position at the university.

“It is the direction that a lot of early stage investment and drug development firms are moving,” Mr. Havrilla, who brought 37 years’ experience in the health care industry to Pitt when he was hired in March 2020. “Their model is to build a startup around a technology. We’re very, very happy with this.”

Word of the Orange Grove partnership comes a day after the Richard King Mellon Foundation announced a $100 million grant to Pitt to build BioForge, a huge biomanufacturing facility at the former LTV Coke Works, now known as Hazelwood Green. Orange Grove CEO Marc Appel wasn’t familiar with the details of BioForge, but said such projects will be complementary to the company’s work at Pitt and the city’s evolution into a biotech hub.

Advertise with us

“Pittsburgh has a lot of potential. It’s a huge research center,” Mr. Appel said. “The ecosystem is in its early stages, so all of that stuff is very helpful.”

Orange Grove, a preclinical drug investment and development firm started in 2019, works with about 50 universities, but only a handful as extensively as Pitt, Mr. Appel said. The company will provide funding and guidance to Pitt researchers, which is necessary to form startup companies and commercialize new therapies.

In a typical arrangement, Pitt would hold the patent for a technology developed by its researchers, but Orange Grove would have exclusive licensing rights. As part of the partnership, William H. Miller, Orange Grove’s head of chemistry, joined Pitt’s external advisory board for novel technologies.

Pitt receives about $1 billion annually in external research funding and ranks among the top 10 universities for National Institutes of Health funding. The bulk of that funding had historically supported basic research, but Mr. Gallagher began shifting Pitt’s research priorities to product commercialization when he was hired in 2014.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699